Skip to main content
Caplight Logo









SiSaf Ltd

SiSaf Ltd

Private
GuildfordHealthcare & Life Scienceshttps://sisaf.com/

Last Round

Series B

Nov 26, 2020

Total Funding Raised

$43.47M

Company Overview

SiSaf Ltd is a biopharmaceutical company that develops RNA therapeutics for conditions such as cancer and rare genetic skeletal disorders using its proprietary Bio-Courier® delivery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticsdrug delivery platformlipid nanoparticleLNPsiRNAmiRNAdrug delivery techbiotech licensingrare genetic disorderscold chain freenucleic acid medicinedrug discoveryprecision medicinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SiSaf Ltd Comparables

Compare SiSaf Ltd with similar companies based on industry and business-model similarity.

SiSaf Ltd comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genevant Sciences
82%
ReCode Therapeutics
78%
Acuitas Therapeutics
78%

SiSaf Ltd Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 26, 2020
Series A ExtensionAug 1, 2018
Series ASep 19, 2016
SeedOct 23, 2013
SeedApr 4, 2011

Key People

Founding team and executive leadership

Suzanne Saffie-Siebert

Chairwoman CEO

Executive Team

John Stanton

Investor, Board Member, COO, Advisor

Executive Team

SiSaf Ltd Investors

Notable investors and investment history

SiSaf Ltd investors
InvestorRounds
Innovation Ulster LimitedSeed, Series A Extension
Future FundSeries B
Invest Northern IrelandSeries A Extension, Seed, Series A
Silicon Valley Global VenturesSeed
Clarendon Fund ManagersSeed
Vickers Venture PartnersSeries A Extension, Series B, Series A
Innovation Ulster LtdSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 26, 2020

    $13M round led by Vickers Venture Partners.

  • Sep 19, 2016

    $4M round led by Vickers Venture Partners.

SiSaf Ltd Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SiSaf Ltd Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SiSaf Ltd's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuildford
Employee Range17
Year Founded2006
Last FundingNov 26, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?